Alginate Hydrogel Improves Anti-Angiogenic Bevacizumab Activity in Cancer Therapy

European Journal of Pharmaceutics and Biopharmaceutics - Netherlands
doi 10.1016/j.ejpb.2017.06.028
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Newly Developed Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer

Oncotarget
Oncology
2017English

Biomarkers of Intrinsic Angiogenic and Anti-Angiogenic Activity in Patients With Endometrial Hyperplasia and Endometrial Cancer

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2001English

Angiostatin and Anti-Angiogenic Therapy in Human Disease

Recent Progress in Hormone Research
2004English

Anti-Angiogenic Therapy for Cancer: Current Progress, Unresolved Questions and Future Directions

Angiogenesis
Cancer ResearchClinical BiochemistryPhysiology
2014English

Anti‐angiogenic Therapies for Gastric Cancer

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2019English

Endothelial Cell Killing by TAK1 Inhibition: A Novel Anti-Angiogenic Strategy in Cancer Therapy

Developmental Cell
BiochemistryDevelopmental BiologyGeneticsCell BiologyMolecular Biology
2019English

Tetrac as an Anti-Angiogenic Agent in Cancer

Endocrine-Related Cancer
Cancer ResearchEndocrinologyOncologyMetabolismDiabetes
2019English

A Plasma Cytokine and Angiogenic Factor (CAF) Analysis for Selection of Bevacizumab Therapy in Patients With Metastatic Colorectal Cancer

Scientific Reports
Multidisciplinary
2015English

Anti-Angiogenic Therapy: From Laboratory to the Patient

Breast Cancer Online
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy